In a phase II clinical study, it was observed that among patients with CCA who had previously undergone therapy and experienced of FGFR2 fusions or rearrangements, the administration of 13.5 mg of oral pemigatinib once daily resulted in an ORR of 35.5% with 38 out of 107 patients achieving a response, including 3 CR and 35 partial responses [108]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.